Blueprint Medicines Corp (BPMC)
107.19
+0.19
(+0.18%)
USD |
NASDAQ |
May 03, 16:00
107.20
+0.01
(+0.01%)
After-Hours: 20:00
Blueprint Medicines Cash from Operations (Quarterly): -78.93M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -78.93M |
| September 30, 2023 | -104.48M |
| June 30, 2023 | -130.48M |
| March 31, 2023 | -122.96M |
| December 31, 2022 | -121.40M |
| September 30, 2022 | -129.89M |
| June 30, 2022 | -118.26M |
| March 31, 2022 | -132.73M |
| December 31, 2021 | -14.11M |
| September 30, 2021 | -95.60M |
| June 30, 2021 | -63.16M |
| March 31, 2021 | -125.78M |
| December 31, 2020 | -24.80M |
| September 30, 2020 | 622.33M |
| June 30, 2020 | -101.16M |
| March 31, 2020 | -109.33M |
| December 31, 2019 | -44.90M |
| September 30, 2019 | -71.70M |
| June 30, 2019 | -81.23M |
| March 31, 2019 | -80.19M |
| Date | Value |
|---|---|
| December 31, 2018 | -67.58M |
| September 30, 2018 | -55.00M |
| June 30, 2018 | -2.859M |
| March 31, 2018 | -49.56M |
| December 31, 2017 | -34.75M |
| September 30, 2017 | -26.52M |
| June 30, 2017 | -27.52M |
| March 31, 2017 | -31.08M |
| December 31, 2016 | -18.80M |
| September 30, 2016 | -18.63M |
| June 30, 2016 | -17.83M |
| March 31, 2016 | 30.75M |
| December 31, 2015 | -13.05M |
| September 30, 2015 | -12.46M |
| June 30, 2015 | -11.06M |
| March 31, 2015 | 4.89M |
| December 31, 2014 | -11.58M |
| September 30, 2014 | -8.566M |
| June 30, 2014 | -8.644M |
| March 31, 2014 | -6.61M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-132.73M
Minimum
Mar 2022
622.33M
Maximum
Sep 2020
-55.19M
Average
-101.16M
Median
Jun 2020
Cash from Operations (Quarterly) Benchmarks
| Apellis Pharmaceuticals Inc | -97.88M |
| Alnylam Pharmaceuticals Inc | -81.52M |
| Ionis Pharmaceuticals Inc | 32.86M |
| Madrigal Pharmaceuticals Inc | -79.93M |
| Sarepta Therapeutics Inc | -242.08M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 78.77M |
| Cash from Financing (Quarterly) | 15.53M |
| Free Cash Flow | -452.91M |
| Free Cash Flow Per Share (Quarterly) | -1.373 |
| Free Cash Flow to Equity (Quarterly) | -84.04M |
| Free Cash Flow to Firm (Quarterly) | -78.43M |
| Free Cash Flow Yield | -6.98% |